{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-310169","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2022-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.154409+00:00","generated_at":"2026-06-21T00:59:15.455287+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ORIC Pharma partners with Pfizer on ORIC-533 Phase 2 combo study; Pfizer invests $25M","bullets":["Pfizer to invest $25M for 5,376,344 shares at $4.65/share in registered direct offering.","ORIC and Pfizer will conduct a Phase 2 study of ORIC-533 combined with elranatamab in multiple myeloma.","Jeff Settleman, Pfizer Oncology CSO, joins ORIC's Scientific Advisory Board.","ORIC retains full ownership of ORIC-533; net proceeds extend cash runway into 1H 2025.","Offering expected to close Dec 23, 2022; no underwriter or placement agent involved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-310169","json":"https://secwatch.observer/filing/0001193125-22-310169.json","markdown":"https://secwatch.observer/filing/0001193125-22-310169.md","text":"https://secwatch.observer/filing/0001193125-22-310169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312522310169/0001193125-22-310169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312522310169/d399008d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:59:15.455287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}